SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Heusschen R, Muller J, Binsfeld M, Marty C, Plougonven E, Dubois S, Mahli N, Moermans K, Carmeliet G, Léonard A, Baron F, Beguin Y, Menu E, Cohen-Solal M, Caers J.
Heusschen R, et al. Among authors: binsfeld m.
Oncotarget. 2016 May 24;7(21):30712-29. doi: 10.18632/oncotarget.8750.
Oncotarget. 2016.
PMID: 27095574
Free PMC article.